nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.04.2005 | Original Paper

Heparanase expression correlates with malignant potential in human colon cancer

verfasst von: T. Nobuhisa, Y. Naomoto, T. Ohkawa, M. Takaoka, R. Ono, T. Murata, M. Gunduz, Y. Shirakawa, T. Yamatsuji, M. Haisa, J. Matsuoka, H. Tsujigiwa, H. Nagatsuka, M. Nakajima, N. Tanaka

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 4/2005

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Heparanase cleaves carbohydrate chains of heparan sulphate proteoglycans and is an important component of the extracellular matrix. This study was designed to determine the relation between heparanase expression and prognosis of patients with colon cancer.

Methods

The study included 54 patients (35 males and 19 females) who underwent colorectal resection for colorectal cancer between January 1992 and December 1994. Expression of heparanase protein and mRNA were determined and correlated with various clinicopathological parameters. In vitro studies were also performed to examine tumor invasion and to test the effects of heparanase inhibition, and in vivo studies were performed to examine tumor metastasis and prognosis.

Results

Heparanase expression was detected in the invasion front of the tumor in 37 of 54 (69%) colon cancer samples, whereas 17 of 54 (31%) tumors were negative. Expression of heparanase was significantly more frequent in tumors of higher TNM stage (P=0.0481), higher Dukes stage (P=0.0411), higher vascular infiltration (P=0.0146), and higher lymph vessel infiltration (P=0.0010). Heparanase expression in colon cancers correlated significantly with poor survival (P=0.0361). Heparanase-transfected colon cancer cells exhibited significant invasion compared with control-transfected colon cancer cells (P=0.001), and the peritoneal dissemination model also showed the malignant potential of heparanase-transfected cells, as assayed by number of nodules (P=0.017) and survival (P=0.0062). Inhibition of heparanase significantly reduced the invasive capacity of cancer cells (P=0.003).

Conclusions

Heparanase is a marker for poor prognosis of patients with colon cancer and could be a suitable target for antitumor therapy in colon cancer.

Albini A (1998) Tumor and endothelial cell invasion of basement membranes. The matrigel chemoinvasion assay as a tool for dissecting molecular mechanisms. Pathol Oncol Res 4: 230–241PubMed

Beahrs OH (1982) Colorectal cancer staging as a prognostic feature. Cancer 50: 2615–2617PubMed

Black DA, Waugh JM (1948) The intramural extension of carcinoma at the descending colon, sigmoid, and rectosigmoid. A Pathologic study. Surg Gynecol Obstet 84: 457–461

Chapuis PH, Dent OF, Fisher R, Newland RC, Pheils MT, Smyth E, Colquhoun K (1985) A multivariate analysis of clinical and pathological variables in prognosis after resection of large bowel cancer. Br J Surg 72: 698–702

Dukes CE, Bussey HJR (1958) The spread of rectal cancer and its effect on progress. Br J Cancer 12: 309–320PubMed

Freeman C, Parish CR (1997) A rapid quantitative assay for the detection of mammalian heparanase activity. Biochem J 325:229–237PubMed

Friedmann Y, Vlodavsky I, Aingorn H, Aviv A, Peretz T, Pecker I, Pappo O (2000) Expression of heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma. Evidence for its role in colonic tumorigenesis. Am J Pathol 157:1167–1175PubMed

Gohji K, Okamoto M, Kitazawa S, Toyoshima M, Dong J, Katsuoka Y, Nakajima M (2001) Heparanase protein and gene expression in bladder cancer. J Urol 166: 1286–1290PubMed

Greenson JK, Isenhart CE, Rice R, Mojzisik C, Houchens D, Martin EWJr (1994) Identification of occult micrometastases in pericolic lymph nodes of Duke’s B colorectal cancer patients using monoclonal antibodies against cytokeratin and CC49. Correlation with long-term survival. Cancer 73: 563–569PubMed

Inoue H, Mimori K, Utsunomiya T, Sadanaga N, Barnard GF, Ueo H, Mori M (2001) Heparanase expression in clinical digestive malignancies. Oncol Rep 8:539–542PubMed

Jackson RL, Busch SJ, Cardin AL (1991) Glycosaminoglycans: molecular properties, protein interactions and role in physiological processes. Physiol Rev 71:481–539PubMed

Kjellen L, Lindahl U (1991) Proteoglycans: structures and interactions. Annu Rev Biochem 60:443–475PubMed

Koliopanos A, Friess H, Kleeff J, Shi X, Liao Q, Packer I, Vlodavsky I, Zimmermann A, Buchler MW (2001) Heparanase expression in primary and metastatic pancreatic cancer. Cancer Res 61:4655–4659PubMed

Kramer RH, Vogel KG, Nicolson GL (1982) Solubilization and degradation of sub-endothelial-matrix glycoproteins and proteoglycans by metastatic tumor cells. J Biol Chem 257:2678–2686PubMed

Marchetti D, Reiland J, Erwin B, Roy M (2003) Inhibition of heparanase activity and heparanase-induced angiogenesis by suramin analogues. Int J Cancer 104:167–174PubMed

Mikami S, Ohashi K, Ushii Y, Nemoto T, Katsube K, Yanagishita M, Nakajima M, Nakamura K, Koike M (2001) Loss of syndecan-1 and increased expression of heparanase in invasive esophageal carcinomas. Jpn J Cancer Res 92: 1062–1073PubMed

Nakajima M, Irimura N, Ferrante DD, Ferrante ND, Nicolson GL (1983) Heparan sulfate degradation: relation to tumor invasive and metastatic properties of mouse B16 melanoma sublines. Science 220:611–613PubMed

Nakajima M, Irimura T, Nicolson GL (1988) Heparanase and tumor metastasis. J Cell Biochem 36:157–167PubMed

Nakajima M, Morikawa K, Fabra A, Bucana CD, Fidler IJ (1990) Influence of organ environment on extracellular matrix degradative activity and metastasis of human colon carcinoma cells. J Natl Cancer Inst 82:1890–1898PubMed

Nakajima M, DeChavigny A, Johnson CE, Hamada JI, Stein CA, Nicolson GL (1991) Suramin. A potent inhibitor of melanoma heparanase and invasion. J Biol Chem 266:9661–9666PubMed

Naomoto Y, Kondo H, Tanaka N, Orita K (1987) Novel experimental models of human cancer metastasis in nude mice: lung metastasis, intraabdominal carcinomatosis with ascites, and liver metastasis. J Cancer Res Clin Oncol 113:544–549PubMed

Newland RC, Chapuis PH, Pheils MT, MacPherson JG (1981) The relationship of survival to staging and grading of colorectal carcinoma: a prospective study of 503 cases. Cancer 47: 1424–1429PubMed

Nishimura Y, Shitara E, Adachi H, Toyoshima M, Nakajima M, Okami Y, Takeuchi T (2000) Flexible synthesis and biological activity of uronic acid-type gem-diamine 1-N-iminosugars: a new family of glycosidase inhibitors. J Org Chem 65:2–11PubMed

Nissen NN, Shankar R, Gamelli RL, Singh A, DiPietro LAI (1999) Heparin and heparan sulphate protect basic fibroblast growth factor from non-enzymic glycosylation. Biochem J 338:637–642PubMed

Ohkawa T, Naomoto Y, Takaoka M, Nobuhisa T, Noma K, Motoki T, Murata T, Uetsuka H, Kobayashi M, Shirakawa Y, Yamatsuji T, Matsubara N, Matsuoka J, Haisa M, Gunduz M, Tsujigiwa H, Nagatsuka H, Hosokawa M, Nakajima M, Tanaka N (2004) Localization of heparanase in esophageal cancer cells: respective roles in prognosis and differentiation. Lab Invest (in press)

Parish CR, Freeman C, Brown KJ, Francis DJ, Cowden WB (1999) Identification of sulfate oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res 59:3433–3441PubMed

Rohloff J, Zinke J, Schoppmeyer K, Tannapfel A, Witzigmann H, Mossner J, Wittekind C, Caca K (2002) Heparanase expression is a prognostic indicator for postoperative survival in pancreatic adenocarcinoma. Br J Cancer 86: 1270–1275PubMed

Takaoka M, Naomoto Y, Ohkawa T, Uetsuka H, Shirakawa Y, Uno F, Fujiwara T, Gunduz M, Nagatsuka H, Nakajima M, Tanaka N, Haisa M (2003) Heparanase expression correlates with invasion and poor prognosis in gastric cancers. Lab Invest 83: 613–622PubMed

Toyoshima M, Nakajima M (1999) Human heparanase. Purification, characterization, cloning, and expression. J Biol Chem 274: 24153–24160PubMed

Vlodavsky I, Eldor A, Haimovitz-Friedman A, Matzner Y, Ishai-Michaeli R, Lider O, Naparstek Y, Cohen IR, Fuks Z (1992) Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation. Invasion Metastasis 12:112–127PubMed

Vlodavsky I, Miao HQ, Benezra M, Lider O, Bar-Shavit R, Schmidt A (1997) Involvement of the extracellular matrix, heparan sulfate proteoglycans and heparan sulfate degrading enzymes in angiogenesis and metastasis. In: Lewis CE, Bicknell R, Ferrara N (eds) Tumor angiogenesis. Oxford University, Oxford, pp 125–140

Wight TN, Kinsella MG, Qwarntromn EE (1992) The role of proteoglycans in cell adhesion, migration and proliferation. Curr Opin Cell Biol 4:793–801PubMed

Titel: Heparanase expression correlates with malignant potential in human colon cancer
verfasst von: T. Nobuhisa
Y. Naomoto
T. Ohkawa
M. Takaoka
R. Ono
T. Murata
M. Gunduz
Y. Shirakawa
T. Yamatsuji
M. Haisa
J. Matsuoka
H. Tsujigiwa
H. Nagatsuka
M. Nakajima
N. Tanaka
Publikationsdatum: 01.04.2005
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 4/2005
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-004-0644-x

Springer Medizin

Heparanase expression correlates with malignant potential in human colon cancer